Federal Contractor Profile
Ophirex, INC
Federal contracting record: $46M obligated across 7 awards from 1 agencies, FY 2017–2025.
Company Profile
UEI (Unique Entity Identifier)
W452WY5E2JQ9
CAGE Code
7JTR0
Parent Organization
Ophirex, INC
Address
5643 PARADISE DR #2, CORTE MADERA, CA, 949251815
First Federal Award
Apr 26, 2017
Most Recent Award
Sep 5, 2025
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- $46M
Department of Defense
100.0% of total obligations
Top NAICS Activity
- $46M
541715
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
5 awards
- $627K
541712
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY)
1 awards
- $149K
541714
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
1 awards
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Mar 19, 2024 | Department of DefenseARMY MED RES ACQ ACTIVITY | 541715 | FOLLOW ON PHASE III RESEARCH AND DEVELOPMENT SBIR FOR PROJECT TITLED, BROAD-SPECTRUM SNAKEBITE ANTIDOTE: ORAL PRODUCT DEVELOPMENT AND IV CLINICAL STUDY | $4.5M |
| Aug 22, 2023 | Department of DefenseARMY MED RES ACQ ACTIVITY | 541715 | DHA PH II SEQL PROPOSAL H2S-0045, TITLE: BROAD-SPECTRUM SNAKEBITE ANTIDOTE: METALLOPROTEASE INHIBITION TO IMPROVE RECOVERY TIME FOLLOWING SNAKEBITE, MEDICAL R & D EGS 23000510 | $1.3M |
| Jun 1, 2023 | Department of DefenseARMY MED RES ACQ ACTIVITY | 541715 | FOLLOW ON PHASE III RESEARCH AND DEVELOPMENT SBIR FOR PROJECT TITLED, BROAD-SPECTRUM SNAKEBITE ANTIDOTE: ORAL PRODUCT DEVELOPMENT AND IV CLINICAL STUDY | $2.2M |
| Apr 7, 2023 | Department of DefenseARMY MED RES ACQ ACTIVITY | 541715 | FOLLOW ON PHASE III RESEARCH AND DEVELOPMENT SBIR FOR PROJECT TITLED, BROAD-SPECTRUM SNAKEBITE ANTIDOTE: ORAL PRODUCT DEVELOPMENT AND IV CLINICAL STUDY | $2.9M |
| Jan 30, 2023 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541715 | ARMY MEDICAL RESEARCH AND DEVELOPMENT SBIR PHASE III CONTRACT TITLED ADVANCEMENT OF ADVANCEMENT BROAD-SPECTRUM SNAKEBITE ANTIDOTE. | $131K |
| Apr 5, 2022 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541715 | FOLLOW ON PHASE III RESEARCH AND DEVELOPMENT SBIR FOR PROJECT TITLED, BROAD-SPECTRUM SNAKEBITE ANTIDOTE: ORAL PRODUCT DEVELOPMENT AND IV CLINICAL STUDY | $14M |
| Feb 8, 2022 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541715 | ARMY MEDICAL RESEARCH AND DEVELOPMENT SBIR PHASE III CONTRACT TITLED ADVANCEMENT OF ADVANCEMENT BROAD-SPECTRUM SNAKEBITE ANTIDOTE. | $206K |
| Jul 28, 2021 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541715 | ARMY MEDICAL RESEARCH AND DEVELOPMENT SBIR PHASE III CONTRACT TITLED ADVANCEMENT OF ADVANCEMENT BROAD-SPECTRUM SNAKEBITE ANTIDOTE. | $1.6M |
| Apr 27, 2021 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541715 | COVID-19 DHA 2018.1 SBIR PHASE III MEDICAL R&D CONTRACT PROPOSAL TITLED: "TARGETING SPLA2 FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) ASSOCIATED WITH SARS-COV-2" LOG #19000053 | $698K |
| Mar 31, 2021 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541715 | ARMY MEDICAL RESEARCH AND DEVELOPMENT SBIR PHASE III CONTRACT TITLED ADVANCEMENT OF ADVANCEMENT BROAD-SPECTRUM SNAKEBITE ANTIDOTE. | $958K |
| Mar 10, 2021 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541715 | DHA SBIR PH II MEDICAL R&D CONTRACT FOR PROPOSAL NO. H2-0440, TITLED: "BROAD SPECTRUM ENVENOMATION TREATMENT". | $550K |
| Nov 24, 2020 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541715 | ARMY MEDICAL RESEARCH AND DEVELOPMENT SBIR PHASE III CONTRACT TITLED ADVANCEMENT OF ADVANCEMENT BROAD-SPECTRUM SNAKEBITE ANTIDOTE. | $657K |
| Sep 1, 2020 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541715 | ARMY MEDICAL RESEARCH AND DEVELOPMENT SBIR PHASE III CONTRACT TITLED ADVANCEMENT OF ADVANCEMENT BROAD-SPECTRUM SNAKEBITE ANTIDOTE. | $2.3M |
| Jun 19, 2020 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541715 | COVID-19 DHA 2018.1 SBIR PHASE III MEDICAL R&D CONTRACT PROPOSAL TITLED: "TARGETING SPLA2 FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) ASSOCIATED WITH SARS-COV-2" LOG #19000053 | $9.9M |
| Jun 1, 2020 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541715 | ARMY MEDICAL RESEARCH AND DEVELOPMENT SBIR PHASE III CONTRACT TITLED ADVANCEMENT OF ADVANCEMENT BROAD-SPECTRUM SNAKEBITE ANTIDOTE. | $3.6M |
| Jul 31, 2019 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541715 | DHA SBIR PH II MEDICAL R&D CONTRACT FOR PROPOSAL NO. H2-0440, TITLED: "BROAD SPECTRUM ENVENOMATION TREATMENT". | $975K |
| Jun 25, 2018 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541714 | DHA PHASE I SBIR PROPOSAL H181-002-0002, BROAD SPECTRUM ENVENOMATION TREATMENT | $149K |
| Apr 26, 2018 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541712 | IGF::OT::IGF SOCOM BAA AWARD PROPOSAL LOG SO150138 FIELD ANTIDOTE FOR SNAKE BITE | $449K |
| Apr 26, 2017 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541712 | IGF::OT::IGF SOCOM BAA AWARD PROPOSAL LOG SO150138 FIELD ANTIDOTE FOR SNAKE BITE | $177K |
Related Contractors
Other companies active in NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY).
Track Ophirex, INC Recompetes Before They Post
Mindy monitors Ophirex, INC's active contracts and alerts you 12 months before they expire — so you can position to compete on recompete.
Get Free Recompete Alerts